KRANZLER JAY D 4
4 · CYPRESS BIOSCIENCE INC · Filed Dec 29, 2010
Insider Transaction Report
Form 4
KRANZLER JAY D
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Stock Options (right to buy)
2010-12-23−152,464→ 0 totalExercise: $3.25Exp: 2012-04-29→ Common Stock (152,464 underlying) - Sale
Common Stock
2010-12-23$6.45/sh−152,464$983,393→ 96,742 total(indirect: By Trust) - Exercise/Conversion
Common Stock
2010-12-23$3.25/sh+152,464$495,508→ 249,206 total(indirect: By Trust)
Holdings
- 625
Common Stock
- 398,692(indirect: By 401(k))
Common Stock
Footnotes (3)
- [F1]The weighted average sale price for the transaction reported was $6.4501, the range of prices were between $6.45 and $6.455. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
- [F2]The shares subject to the option are fully vested
- [F3]Between January 1, 2010 and December 14, 2010, 196,440 shares of Common Stock were transfered into the Cypress Bioscience, Inc. 401(k) plan, of which the Reporting Person is the trustee and has voting power over such shares.